Patents by Inventor Curtis L. Atkin

Curtis L. Atkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5872233
    Abstract: A method of purifying Mycoplasma arthritidis mitogen (MAM) to electrophoretic and sequence homogeneity is disclosed. A preparation of MAM purified according to this method was used to determine the sequence of the N-terminal 54 amino acids of MAM. A synthetic peptide consisting of amino acids 15-32 inhibited MAM-induced cell proliferation in vitro. The sequence of the N-terminal 54 amino acids was reverse translated, nucleotide probes were designed therefrom, and the MAM gene was selected from a genomic library. The MAM gene was sequenced and found to be contained on a 1107 bp DNA fragment. The primary translation product contains a 39 amino acid signal sequence and a 213 amino acid mature MAM (molecular weight 25,294). Amino acid sequence comparisons of MAM to bacterial and murine tumor virus superantigens showed regions of conservative sequence homology, including the region capable of inhibiting cell proliferation.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: February 16, 1999
    Assignee: University of Utah Research Foundation
    Inventors: Barry C. Cole, Curtis L. Atkin, Arnold R. Oliphant, Ann Pole
  • Patent number: 5795974
    Abstract: The gene encoding the superantigen Mycoplasma arthritidis T-cell mitogen (MAM) was molecularly cloned. The mam gene was modified by site-directed mutagenesis to change UGA codons, which in mycoplasmas are read as tryptophan codons instead of universal stop codons, to UGG codons such that the gene could be expressed in standard expression systems. Recombinant MAM, including extra amino acid residues at the N- and C-termini, were expressed and discovered to be biologically active. Certain amino acid substitutions in active regions of the protein also yield biologically active MAM proteins. A method of diagnosing rheumatoid arthritis using recombinant MAM protein in an ELISA assay is disclosed.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: August 18, 1998
    Assignee: University of Utah Research Foundation
    Inventors: Barry C. Cole, Curtis L. Atkin, Kevin L. Knudtson
  • Patent number: 5639869
    Abstract: A method of purifying Mycoplasma arthritidis mitogen (MAM) to electrophoretic and sequence homogeneity is disclosed. A preparation of MAM purified according to this method was used to determine the sequence of the N-terminal 54 amino acids of MAM. A synthetic peptide consisting of amino acids 15-32 inhibited MAM-induced cell proliferation in vitro. The sequence of the N-terminal 54 amino acids was reverse translated, nucleotide probes were designed therefrom, and the MAM gene was selected from a genomic library. The MAM gene was sequenced and found to be contained on a 1107 bp DNA fragment. The primary translation product contains a 39 amino acid signal sequence and a 213 amino acid mature MAM (molecular weight 25,294). Amino acid sequence comparisons of MAM to bacterial and murine tumor virus superantigens showed regions of conservative sequence homology, including the region capable of inhibiting cell proliferation.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: June 17, 1997
    Assignee: University of Utah
    Inventors: Barry C. Cole, Curtis L. Atkin, Arnold R. Oliphant, Ann Pole
  • Patent number: 4335716
    Abstract: A composition and method for use with peritoneal dialysis patients for preventing or treating dialysis induced peritonitis. The method utilizes a flush solution of normal saline to prepare the peritoneal cavity for infusion of a dilute iodine solution which operates to kill pathogenic organisms contained therein. The dilute iodine solution has a combination I.sub.2 and HIO concentration in the approximate range of 0.1 ppm to 15 ppm and requires residence time of less than five minutes to provide an effective kill. The serial application of flush and dilute iodine solutions may be applied as part of a regular peritoneal dialysis program to prevent peritonitis or may be used with greater frequency as treatment for existing dialysis induced peritonitis.
    Type: Grant
    Filed: November 21, 1980
    Date of Patent: June 22, 1982
    Assignee: University of Utah Research Foundation
    Inventors: Robert L. Stephen, Carl Kablitz, Dietz van Dura, Curtis L. Atkin, Stephen C. Jacobsen
  • Patent number: 4235230
    Abstract: A composition and method for use with peritoneal dialysis patients for preventing or treating dialysis induced peritonitis. The method utilizes a flush solution of normal saline to prepare the peritoneal cavity for infusion of a dilute iodine solution which operates to kill pathogenic organisms contained therein. The dilute iodine solution has a combination I.sub.2 and HIO concentration in the approximate range of 0.1 ppm to 15 ppm and requires residence time of less than five minutes to provide an effective kill. The serial application of flush and dilute iodine solutions may be applied as part of a regular peritoneal dialysis program to prevent peritonitis or may be used with greater frequency as treatment for existing dialysis induced peritonitis.
    Type: Grant
    Filed: February 12, 1979
    Date of Patent: November 25, 1980
    Assignee: University of Utah
    Inventors: Robert L. Stephen, Carl Kablitz, Dietz van Dura, Curtis L. Atkin, Stephen C. Jacobsen